NIPH Clinical Trials Search

JAPANESE
国立保健医療科学院
UMIN ID: UMIN000056116

Registered date:15/11/2024

Effect of amino acid mixture on blood glucose

Basic Information

Recruitment status Pending
Health condition(s) or Problem(s) studiedHealthy adults who feel they do not get enough physical activity
Date of first enrollment2024/11/16
Target sample size50
Countries of recruitmentJapan
Study typeInterventional
Intervention(s)amino acid mixture, single dose foods not containing amino acid mixture, single dose

Outcome(s)

Primary OutcomeBlood glucose levels
Secondary OutcomeInsulin concentration Amino acid concentration

Key inclusion & exclusion criteria

Age minimum20years-old
Age maximum65years-old
GenderMale and Female
Include criteria
Exclude criteria(1)Subjects who use oral medication affecting blood glucose. (2)Subjects who constantly use supplements and/or functional foods (including Food for Specified Health Uses) affecting blood glucose. (3)Subjects who need medical treatment for diabetes. (4)Subjects who contract or are under treatment or are medical history for serious diseases (e.g.,liver disease, kidney disease, and/or heart disease), thyroid gland disease, adrenal gland disease, and/or metabolic disorder. (5)Subjects who have a operational history of digestive disease affecting digestion and absorption. (6)Subjects who are judged as unsuitable for the study based on the results of blood tests by the investigator at screening. (7)Subjects who have donated 400 mL of blood within 12 weeks prior to the start of the study and 200 mL of blood within 4 weeks and component blood donations (plasma component and platelet component blood donations) within 2 weeks prior to the start of the study. Also, considering the total amount of blood collected during the study, those who plan to donate blood within 12 weeks of the study. (8)Subjects who are diagnosed as anemic and not suitable for frequent collection of blood. (9)Subjects who developed diarrhea or took antibiotics within one week retroactive to the examination. (10)Subjects who are planning to participate in other clinical studies. (11)Subjects who are planning to become pregnant after informed consent for the current study or are pregnant or lactating. (12)Subjects who are judged as unsuitable for the study by the investigator for other reasons. (13) Glucose tolerance test (75 g OGTT): Fasting blood glucose level greater than 110 mg/dL, or 2-hour blood glucose level greater than 200 mg/dL (14) Glucose tolerance test (75 g OGTT): The blood glucose level does not rise at all. The behavior of the blood glucose level change is N-shaped or M-shaped.

Related Information

Contact

public contact
Name Kyoko MIURA
Address 1-1, Suzuki-cho, Kawasaki-ku, Kawasaki-shi, Kanagawa, Japan Japan 210-8681
Telephone 07043255184
E-mail kyouko.miura.jt9@asv.ajinomoto.com
Affiliation Ajinomoto Co., Inc. Functional Ingredients Group Wellness Solution Development Center
scientific contact
Name Shinobu Nishitani
Address 1-1, Suzuki-cho, Kawasaki-ku, Kawasaki-shi, Kanagawa, Japan Japan
Telephone 08010457701
E-mail shinobu.nishitani.vx8@asv.ajinomoto.com
Affiliation Ajinomoto Co., Inc. Functional Ingredients Group Wellness Solution Development Center Institute of Food Sciences and Technologies Food Products Division